The public offering is a significant financial move for Aquestive, providing essential funds for advancing its product pipeline. This could lead to positive investor sentiment, as the development and commercialization of Anaphylm™ and Libervant™ could open new revenue streams and enhance Aquestive's competitive edge in the biotech sector. However, the impact on the stock price will also depend on market conditions and investor perceptions of the company's growth prospects.